Alexandra Gomez-Arteaga, MD, on The Benefit of Orca-T Over PTCy HCT
The Assistant Professor of Medicine at Weill Cornell Medical College shared the background rationale of her retrospective analysis presented at Tandem 2024.
“Currently for myeloablative conditioning, there's no real standard way of how we do GVHD prophylaxis. While last year the findings at ASH from the BMT1703 [study] showed that post-transplant cyclophosphamide, MMF and tacrolimus was better than tac/methotrexate in the reduced intensity conditioning. And now it's a new standard of care, everyone is using post-transplant cyclophosphamide in the reduced intensity conditioning. When we actually translate this to the myeloablative setting, there is no standard of care.”
Orca-T allogeneic cell therapy showed a benefit in non-relapse mortality, relapse free survival (RFS), and overall survival (OS) in treated patients with hematological malignancies compared with posttransplant cyclophosphamide (PTCy)-based myeloablative conditioning peripheral blood stem cell hematopoietic cell transplant, according to a retrospective analysis. GvHD free survival with Orca-T was also higher when compared with PTCy (73% vs 54%), and RFS and OS remained high at 2 years post Orca-T. The cell therapy is being evaluated in a randomized Phase 3 registrational trial (NCT05316701).
Data from the analysis were presented by Alexandra Gomez Arteaga, MD, Assistant Professor of Medicine and Anne Moore, MD, Clinical Scholar in Hematology-Oncology, Weill Cornell Medical College, at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024.
CGTLive spoke with Arteaga to learn more about Orca-T and the retrospective analysis. She described the rationale of the study and how there is no standard of care in the myeloablative setting to definitively compare Orca-T against. She went over how the analysis was put together and some of the findings.
View more coverage of the 2024 Tandem Meeting now.
REFERENCE
Gomez-Arteaga A, Oliai C, Patel SS, et al. A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Abstract #59
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
